Retatrutide

Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors. This combination aims to maximize metabolic benefits by enhancing insulin secretion, reducing appetite, and increasing energy expenditure. Phase 2 trial data showed mean body weight reductions of up to 17.5% at 24 weeks, making it a promising candidate for further research.

Black Pearl Labs offers retatrutide at research-grade purity for laboratory investigation only. Not for human consumption.